---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-225848"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2026-05-15T15:49:09+00:00"
generated_at: "2026-05-15T15:53:10.861472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026

## Summary
- Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.
- Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.
- FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.
- Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.
- R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY).

## SEC filing metadata
- accession: 0001193125-26-225848
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2026-05-15T15:49:09+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/prok-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-225848
- JSON: https://secwatch.observer/filing/0001193125-26-225848.json
- Plain text: https://secwatch.observer/filing/0001193125-26-225848.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported the first quarter ended March 31, 2026 results: net income Net loss before noncontrolling interest was $42.6 million.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss before noncontrolling interest was $42.6 million
  - Result: reported results
  source text: ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.